New drug combo tested in fight against tough liver cancer
NCT ID NCT07413354
Summary
This study is testing a combination of an immunotherapy drug (tislelizumab) and a traditional Chinese herbal granule (Huaier) as the first treatment for advanced liver cancer that cannot be removed by surgery. It will involve 94 patients to see if this combo can shrink tumors, control the disease, and improve patients' quality of life better than past treatments. The main goal is to measure how many patients see their tumors shrink significantly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan 430030, Hubei, China
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.